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Evidence for a relationship between T4 and T3 and glucose metabolism appeared over 100 years ago when the inﬂuence of thyroid
hormone excess in the deterioration of glucose metabolism was ﬁrst noticed. Since then, it has been known that hyperthyroidism
is associated with insulin resistance. More recently, hypothyroidism has also been linked to decreased insulin sensitivity. The
explanation to this apparent paradox may lie in the diﬀerential eﬀects of thyroid hormones at the liver and peripheral tissues
level. The purpose of this paper is to explore the eﬀects of thyroid hormones in glucose metabolism and analyze the mechanisms
whereby alterations of thyroid hormones lead to insulin resistance.
1.Introduction
The eﬀects of T4 and T3 have a large impact on glucose
homeostasis. This concept was acknowledged by Nobel Prize
winner Dr. Bernardo Alberto Houssay in his lecture in
1947 “The blood sugar and the production and consumption
of glucose are kept within normal bounds, therefore there
is an equilibrium between the glands of internal secretions
which reduce the blood sugar (pancreas) and those which
raise it (anterohypophysis, adrenals, thyroid, etc.)”. Thyroid
hormones exert both insulin agonistic and antagonistic
actions in diﬀerent organs. However, this occurs in a ﬁne
balance necessary for normal glucose metabolism. Deﬁcit
or excess of thyroid hormones can break this equilibrium
leading to alterations of carbohydrate metabolism. Overt
hyperthyroidism has been related to glucose intolerance and
even ketoacidosis. With regards to hypothyroidism, cases of
hypoglycemiahavebeenreported intheliteraturedespitethe
fact that peripheral insulin resistance may be present.
In the century that has elapsed, since the ﬁrst obser-
vations of uncontrolled glucose metabolism in thyrotoxic
diabetic patients [1], new pathways involved in the regu-
lation of glucose homeostasis by thyroid hormones have
been unveiled. Novel ﬁndings include the stimulation of
hepatic glucose production by thyroid hormones acting via
a sympathetic pathway from the hypothalamus [2]a n d
the discovery of transcriptional regulators of metabolic and
mitochondrial genes that, inﬂuenced by intracellular T3
levels, may contribute to the development of insulin resis-
tance [3]. The calorigenic-thermogenic activity of T3 long
ascribed solely to uncoupling of mitochondrial oxidative
phosphorylation has recently been related to T3-induced
gating of mitochondrial permeability transition pore (PTP)
of the inner mitochondrial membrane where the whole T3
transduction pathway integrates genomic and nongenomic
activities of T3 in regulating mitochondrial energetics [4].
In this paper, we summarize the eﬀects of thyroid
hormones in glucose metabolism and its alterations when
thyroid dysfunction is present.
2. Effects of Thyroid Hormones on Glucose
Metabolism(Figure1)
2.1. Direct Eﬀects of Thyroid Hormones at the Liver Level
(Table 1). Thyroid receptor-mediated eﬀects on gene tran-
scription and translation are key in the regulation of
glucose metabolism. According to the results of studies with
complementary DNA (cDNA) microarray analysis in mouse
liver,thisorganisamajortargetofthyroidhormones.Several
genes involved in gluconeogenesis, glycogen metabolism,
and insulin signaling that are regulated by thyroid hormones
have been identiﬁed. In the study by Feng et al. [5], RNA2 Journal of Thyroid Research
Thyrotoxicosis
Thyrotoxicosis
Increased
glucose
intestinal
absorption
Hypothalamic
paraventricular
nucleus
TH
Sympathetic
projections
Thyrotoxicosis
Increased liver
glyconeogenesis
and
glycogenolysis
Thyrotoxicosis
Liver insulin
resistance
β cell apoptosis
Glycemia Increased β
cell function
Hypothyroidism
P
e
r
i
p
h
e
r
a
l
i
n
s
u
l
i
n
r
e
s
i
s
t
a
n
c
e
Increased glucose
utilisation
↑Glut 4
TH
TH
Figure 1:Eﬀectsofthyroidhormonesonglucosemetabolismineuthyroid(solidlines),hyperthyroid(rough-dashedlines),andhypothyroid
conditions (ﬁne-dashed lines). TH: thyroid hormones.
fromhypothyroidmicetreatedwithT3wasprepared,labeled
withﬂuorescentdye,andhybridizedwiththecDNAmicroar-
ray. An increase in glucose-6-phosphatase mRNA expression
with T3 was reported. This enzyme hydrolyzes glucose-6-
phosphate and completes the ﬁnal step in gluconeogenesis
and glycogenolysis, therefore playing an important role in
the homeostatic regulation of blood glucose levels. Another
ﬁnding was a decrease in mRNA expression of Akt2 (protein
kinase B), a serine/threonine kinase that is an essential mole-
culeintheinsulinsignalingpathway.Akt2hasbeenshownto
promote glycogen synthesis in liver by inactivating glycogen
synthase kinase 3. Thus, a decrease in Akt2 activity would
decrease glycogen synthesis explaining the antagonistic
insulin eﬀect of thyroid hormones at the liver. Moreover, an
induction of β2-adrenergic receptor mRNA and repression
of inhibitory G protein (Gi) RNA of the adenylate cyclase
cascade by T3 were also reported. All these results are in
favour of a permissive inﬂuence of T3 in the glycogenolytic
and gluconeogenic eﬀects of epinephrine and glucagon.
Other hepatic gluconeogenic enzymes that have been found
to be positively regulated by thyroid hormones include
phosphoenolpyruvate carboxykinase (PEPCK), the enzyme
that catalyzes the rate-controlling step of gluconeogenesis
[6] and pyruvate carboxylase, involved in the synthesis of
oxaloacetate from pyruvate [7]. The catalytic activity of
pyruvate carboxylase has been found increased approxi-
mately 2-fold in hyperthyroid rats compared with untreated
or treated euthyroid controls.
Another mechanism, whereby thyroid hormones are
known to increase hepatic glucose output, is through inc-
reased hepatic expression of the glucose transporter GLUT2
[8] as previously shown in a rat model where GLUT2 protein
concentration in crude liver membranes was twice as high in
chronically hyperthyroid versus hypothyroid animals.
It has been previously reported that, despite an expected
resistance towards the insulin inhibitory eﬀect on gluco-
neogenesis, the transcription of several enzymes involved
in lipid synthesis or lipid metabolism is increased in
hyperinsulinemic, insulin-resistant mice [9]. Furthermore,
T3 induction of lipogenesis through the transcriptional
activation of malic enzyme, involved in fatty acid synthesis,
has been previously reported [10]. Therefore, it is possible
that by the induction of lipogenic enzymes, T3 could be
further aggravating the dysregulation of liver glucose and
lipid metabolism characteristic of insulin resistance.
As a result of the long time quest for thyroid analogs
that possess the favourable actions on metabolism without
the unwanted thyroid cardiac eﬀects, an indirect way of
learning about T3 action in the diﬀerent tissues has emerged
[11]. The diﬀerential distribution of thyroid receptor (TR)
isoforms in the tissues has been key for the development
of these analogs. With regards to lipogenesis, carbohydrate-
response element-binding protein (ChREBP) is a major
transcription factor controlling the activation of glucose-
induced lipogenesis in liver and is a direct target of thyroid
hormones in liver and white adipose tissue (WAT), the two
main lipogenic tissues in mice. ChREBP is shown to be
speciﬁcally regulated by TRbeta but not by TRalpha in vivo,
inliverwhereTRbetarepresents80%ofthethyroidhormone
bound TR, but also in WAT where both TR isoforms are
expressed [12]. Although the area of thyroid analogs is
beyond the scope of this paper, it is to be mentioned thatJournal of Thyroid Research 3
Table 1:Directeﬀects ofT3on genes thatregulateglucosehomeostasisat theliver and peripheraltissues(muscle,fattissue,andﬁbroblasts).
Gene Expression Site Net eﬀect
glucose-6-phosphatase [5] Increase liver Increase gluconeogenesis and glycogenolysis
protein kinase B (Akt2) [5] decrease liver Decrease glycogen synthesis
β2-adrenergic receptor [5] Increase liver Increase gluconeogenesis and glycogenolysis
inhibitory G protein (Gi) [5] decrease liver Increase gluconeogenesis and glycogenolysis
phosphoenolpyruvate carboxykinase (PEPCK) [6] Increase liver Increase gluconeogenesis
pyruvate carboxylase (PC) [7] Increase liver Increase gluconeogenesis
GLUT2 [8] Increase liver Increase glucose output
malic enzyme [10] Increase liver lipogenesis
Carbohydrate-response element-binding protein
(ChREBP) [12] Increase liver and fat tissue lipogenesis
GLUT1 [14] Increase peripheral tissues Increase glucose transport (basal)
GLUT4 [14] Increase peripheral tissues Increase glucose transport (insulin-induced)
β2-adrenergic receptor [20] Increase Peripheral tissues Increase lipolysis
phosphoglycerate kinase (PGK) [15] Increase peripheral tissues Increase glycolysis
Hypoxia-inducible factor 1 (HIF-1α)[ 15] Increase peripheral tissues Increase glycolysis
PPAR gamma coactivator-1 alpha (PGC-1 alpha)
[27] Increase peripheral tissues Increase mitochondrial biogenesis and function
uncoupling protein 3 (UCP3) [17] Increase peripheral tissues Increase mitochondrial energy expenditure
some thyromimetic analogs, such as 3,5-l-diiodothyronine
(T(2)), exert their beneﬁcial action on metabolism, without
inducing a thyrotoxic state, through a mechanism that
does not involve binding to thyroid hormone receptors
[13]. In rats fed a high-fat diet, the addition of T(2) to
lipid-overloaded cells resulted in reduction in lipid con-
tent; downregulation of peroxisome proliferator-activated
receptors (PPAR)α,P P A R γ, and alternative oxidase (AOX)
expression; increase in PPARδ expression; and stimulation
of mitochondrial uncoupling thus preventing and reversing
hepatic steatosis in this animal model. Surprisingly, in this
study, these lipid-lowering actions not mediated by TR were
also observed with T3.
To summarize, all these ﬁndings have helped to under-
standthatthyroidhormones haveinsulin antagonisticeﬀects
at the liver that lead to an increased glucose hepatic output,
via an enhanced rate of gluconeogenesis and glycogenolysis.
With regards to lipid metabolism, both lipogenesis and
lipolysis are stimulated by T3. However, in the context
of insulin resistance, the conversion of glucose into fatty
acids together with nonsuppressed gluconeogenesis is sim-
ply perpetuating the hyperinsulinemic state. Furthermore,
nutritional inﬂuences, such as those of high-fat diets, should
also be taken into consideration as modiﬁers of the eﬀects of
thyroid hormones on insulin sensitivity.
2.2.DirectEﬀectsofThyroidHormonesatthePeripheralTissue
Level (Table 1). Opposite to what occurs at the liver level,
at peripheral tissues, thyroid hormones have been shown to
exert some of their actions synergically with insulin. The
upregulation of the expression of genes such as GLUT-4
[14] or phosphoglycerate kinase (PGK) [15], involved in
glucose transport and glycolysis respectively, is a good proof
of concept.
In skeletal muscle, the main site of insulin-mediated
glucose disposal, glucose transporter GLUT4, is induced
by T3, revealing that it can increase basal and insulin-
stimulated glucose transport in this tissue [14]. Another T3
targetinskeletalmuscleismitochondrialuncouplingprotein
3 (UCP3). Unveiling this association may be important
since progressive reduction of UCP3 levels results in insulin
resistanceaccompaniedbydecreasedfattyacidoxidationand
a less intense Akt/PKB and 5 adenosine monophosphate-
activated protein kinase (AMPK) signaling [16]. Although
discrepancies between the regulation by T3 of UCP3 expres-
sion in rats, humans, and mice have been observed, the rat
model has shed some light into T3 actions in this tissue. T3
intravenous (i.v.) administration in hypothyroid rats showed
a rise in serum fatty acid levels concomitant with a rapid
increase in UCP3 expression in gastrocnemius muscle. These
ﬁndings point to UCP as a possible molecular determinant
of the action of T3 on energy metabolism [17].
Liver actions of the naturally occurring thyromimetic
analog T2 have been discussed above. However, T2 actions
have been also explored in skeletal muscle [18]. In a model
of high-fat diet-induced insulin resistance in rat, the admi-
nistration of T2, on the gastrocnemius muscle, induced
remarkable changes on the metabolic/structural phenotype
and insulin signaling. T2 increased insulin-stimulated Akt
phosphorylation levels, the muscle contents of fast/glycolytic
ﬁbers and sarcolemmal GLUT4. Moreover, glycolytic enz-
ymes and associated components were upregulated together
with phosphofructokinase activity.
The result of cDNA microarray analysis on skeletal
muscle of a group of healthy men receiving 75μg/d of T34 Journal of Thyroid Research
for 14 days has shown that not only genes with agonistic
insulin eﬀects but several others with antagonistic insulin
eﬀects are upregulated by treatment with T3 [19], under-
lying the pleiotropic eﬀect of thyroid hormone in energy
metabolism.cDNAarraydatahavealsoprovidedamolecular
basis to the eﬀect of T3 on adipose tissue. In human
adipocytes, T3 increases the mRNA levels of the lipolytic
β2-AR, favouring catecolamine-induced lipolysis and it also
downregulates Sterol regulatory element binding protein
(SREBP1c), involved in lipogenesis, which may constitute a
link between hyperthyroidism and insulin resistance [20].
Skin ﬁbroblasts have been also used to study thyroid
hormone-responsive genes involved in metabolism in
human cells. Although they are not as metabolically active
as hepatic cells, they are easily obtained and also, thyroid
hormone-responsive.Inculturedhumanﬁbroblasts,Moeller
et al. [15] observed that, opposite to a posttranscrip-
tional regulation as reported for other growth factors and
hormones, the mRNA of the transcription factor HIF-1α
(Hypoxia-inducible factor 1), a key mediator of glycolysis,
increased in response to T3. As the glucose transporter
GLUT1, several enzymes of glycolysis, and the lactate
exporter SLC16A3 were all also found induced by T3 and
are target genes of the transcription factor HIF-1α, the
authors postulated that the eﬀect of thyroid hormones on
the induction of these genes most probably was indirect
and HIF-1α mediated. Furthermore, a new mechanism of
thyroid action was unraveled by this group of researchers
[21]. It was shown that T3 bound to TRbeta, in lieu of
initiating gene transcription in the nucleus, activates the
phosphatidylinositol 3-kinase (PI3K) signaling pathway in
the cytosol in order to activate HIF-1α gene expression.
At the cellular level, thyroid hormones can also increase
mitochondrial biogenesis, fatty acid oxidation, and TCA
cycle activity [22]. These ﬁndings are quite relevant since the
role of mitochondrial dysfunction, leading to cellular lipid
excess and impaired oxidative metabolism, has been clearly
demonstrated in the pathogenesis of type 2 diabetes [23–25].
Furthermore, it has been described that in skeletal muscle,
the lack of thyroid hormones might dysregulate mito-
chondrial gene expression [26]. PPAR gamma coactivator-
1 alpha (PGC-1 alpha), a key transcriptional regulator of
mitochondrial content and function, fatty acid oxidation,
and gluconeogenesis, has been involved in the process
whereby thyroid hormones regulate mitochondrial function
[3]. It has been shown that PGC-1 alpha gene expression
is increased by T3, as much as 13-fold 6 hours after T3
treatment[27].TheregulationpatternofT3onPGC-1alpha
is complex and may occur through nongenomic activation
of kinases to induce the expression of PGC-1 alpha or
through transcriptional upregulation via the presence of
a thyroid responsive element (TRE) in the PGC-1 alpha
promoter or by genomic upregulation of a transcription
factor (via a TRE), which then binds to the PGC-1 alpha
promoter and increases PGC-1 alpha transcription [28]. It
is hypothesized that PGC-1 alpha can be dysregulated by
reduced T3 levels [3], thus contributing to insulin resistance.
Not only low circulating but also, intracellular T3 levels,
could count for this matter. A lower expression and activity
of type 2 iodothyronine-deiodinase (D2), the enzyme that
is key for the conversion of T4 into T3 in muscle and
thus, ampliﬁes thyroid hormone signaling in individual cells,
has been found linked to insulin resistance [29, 30]. If
PGC-1 alpha eﬀects on mitochondrial gene expression may
indeed be regulated by thyroid hormone, normal activity of
deiodinase type 2 is very relevant. Several factors, related
to this enzymatic activity, are being currently studied. Bile
acids are potent stimulators of the enzyme and may play an
important role in the relationship between thyroid action
and glucose metabolism [31]. On the other hand, the natural
occurrence of polymorphisms of deiodinase type 2 such as
Thr92Ala,withaloweractivity,hasalsobeenimplicatedwith
increased risk for diabetes type 2 [29].
2.3. Indirect Eﬀects of Thyroid Hormones to the Liver. It has
been shown that the hypothalamus can modulate endoge-
nous glucose production by using functionally reciprocal
sympathetic and parasympathetic autonomic outputs to
the liver [32]. Moreover, a sympathetic pathway from the
hypothalamic paraventricular nucleus to the liver has been
proposed as a central pathway for modulation of hepatic
glucose metabolism by thyroid hormone [33]. Klieveric et
al. [33] demonstrated that upon selective administration to
the paraventricular nucleus (PVN), T3 increases endogenous
glucose production and plasma glucose, and that these
hypothalamic T3 eﬀects are mediated via sympathetic pro-
jections to the liver. In order to arrive to such remarkable
ﬁndings, the authors worked with euthyroid rats treated
with methimazole and T4. First they administered an
intracerebroventricular (i.c.v.) T3 or vehicle (Veh) infusion,
and there was a signiﬁcant increase in plasma glucose
compared with Veh-treated rats. This meant that central
T3 infusion could reproduce the characteristic increase in
hepatic glucose output of thyrotoxicosis. To further identify
the neuroanatomic region responsible for these changes, the
authors infused T3 within the hypothalamus at the PVN.
A similar response was obtained, that was independent of
plasma T3, insulin, and corticosterone concentrations. They
repeated the experiment in surgically hepatic sympathec-
tomized animals (HSx) and sham-denervated animals. HSx
animals showed a decrease of endogenous glucose output
uponhypothalamicT3infusion.Theprincipalﬁndingofthis
study is the description of a neural (autonomic) modulation
of hepatic glucose metabolism by T3 at the hypothalamus
that takes place independently of plasma glucoregulatory
hormone concentrations.
3. InsulinResistance asa Consequenceof
Hyperthyroidism
Thyrotoxic subjects frequently show impaired glucose tol-
erance. This is a result of increased glucose turnover with
increased glucose absorption through the gastrointestinal
tract,postabsorptive hyperglycemia,elevatedhepatic glucose
output,withelevatedfastingand/orpostprandialinsulinand
proinsulin levels, elevated free fatty acid concentrations and
elevated peripheral glucose transport and utilization. The
literature about this topic is vast and has been previouslyJournal of Thyroid Research 5
comprehensively reviewed by Dimitriadis and Raptis [34].
Thyrotoxic diabetic patients are more prone to ketosis [35].
Although ketoacidosis may result per se from the insulin
resistance present in thyrotoxicosis, the stimulatory action of
thyroid hormones in excess on lipolysis and free fatty acids
availability can also contribute to increased ketogenesis [36].
3.1. Increased Hepatic Glucose Output in Hyperthyroidism.
Thyrotoxicosis has been reported to increase endogenous
glucose production in the liver in the basal state and to
decrease hepatic insulin sensitivity in humans [37]. The
diﬀerent mechanisms to explain this phenomenon include
increased rates of gluconeogenesis and glycogenolysis [38]
mainly explained by the above-mentioned eﬀects on the liver
by thyroid hormones. To summarize, these eﬀects include
thyroid receptor-mediated eﬀects on liver gene transcription
[5], increased sympathetic action in the liver mediated by
hypothalamus [33], and increased concentrations of the
GLUT2 glucose transporters in the liver plasma membrane
that allows for glucose eﬄux [8, 39] together with increased
concentration of free fatty acids in plasma [40].
3.2. Peripheral Tissues Glucose Metabolism in Hyperthy-
roidism. The interpretation of the eﬀects of hyperthyroidism
on glucose utilization by peripheral tissues is by far the most
complexissueonthistopic.Ononehand,theratesofglucose
uptake in peripheral tissues have been found increased
by thyroid hormones, suggesting that glucose utilization is
highly increased, specially in skeletal muscle [34, 37, 41–44].
This increased utilization, as shown by indirect calorimetry
duringeuglycemichyperinsulinemicclamps,ismainlydueto
an increase in insulin-stimulated glucose oxidation rates [43,
45–48]. However, a decrease in insulin-stimulated nonox-
idative glucose disposal, through reduced glycogenogenesis
[43, 44, 49], takes place, with intracellular glucose being
redirected towards glycolysis and lactate formation. The
release of lactate from peripheral tissues back to the liver is
a major contributor to the Cori cycle where more hepatic
glucose is being produced [43, 49–51].
Although glucose intolerance in hyperthyroidism can
be easily explained by hepatic insulin resistance with-
out involvement of peripheral tissues, impaired insulin-
stimulated peripheral glucose uptake has also been proven
in some studies. By means of the arteriovenous diﬀerence
technique in the forearm muscles of hyperthyroid subjects
after the consumption of a mixed meal, it has been clearly
demonstrated that muscle blood ﬂow is increased, masking
a defect in insulin-stimulated glucose uptake [52]. Moreover,
in disagreement with previous reports [41, 45], Shen et al.
[53] also described decreased peripheral insulin sensitivity in
hyperthyroidism.
Alternative explanations for peripheral insulin resistance
in hyperthyroidism include an increased secretion of bioac-
tive mediators (adipokines) such as interleukin 6 (IL6) and
tumour necrosis factor a (TNFα) from adipose tissue in
hyperthyroidism [54]. These adipokines, that exert both
proinﬂammatory and insulin resistant eﬀects, have been
found elevated in hyperthyroid women [54].
3.3. Insulin and Glucagon Secretion and Degradation in
Hyperthyroidism. Inhyperthyroidism, decreased, normal,or
even increased levels of plasma insulin have been reported
[34]. However, a rather consistent ﬁnding has been the
increased degradation of insulin in hyperthyroid subjects
[43, 55]. It has been postulated that, in the long run, severe
thyrotoxicosis can lead to irreversible pancreatic damage
[56, 57].
With regards to glucagon, its secretion and metabolic
clearance rates have been reported increased, explaining the
normal fasting plasma levels described in hyperthyroidism
[58].
3.4. Subclinical Hyperthyroidism and Insulin Resistance.
Subclinical hyperthyroidism has also been associated with
insulin resistance [59–61] in some but not all studies [62].
The heterogenous nature of this condition can partly explain
this controversy. Endogenous subclinical hyperthyroidism
may have a larger impact on glucose metabolism due to its
chronicityandhigherT3levelswhencomparedtoexogenous
administration of T4 [61].
4. HypothyroidismCanAlso Lead to
InsulinResistance
Althoughseldomhappening,hypothyroidpatientscanexpe-
rience hypoglycaemia. This phenomenon can be interpreted
in the light of reduced levels of gluconeogenesis leading to
decreased liver glucose output [63, 64]. On the other hand,
insulin resistance has been shown to be present in peripheral
tissuesinhypothyroidanimalmodels[65,66].Hence,apoor
utilization of glucose in hypothyroidism may be oﬀset by a
reduced release to circulation maintaining a balance of the
glucose metabolism.
4.1. Animal Studies Showing Insulin Resistance in Hypothy-
roidism. Studies performed in adipocytes and skeletal mus-
cle of rats made hypothyroid have shown that these tissues
are less responsive to insulin with regards to glucose
metabolism [63, 65–69] .C z e c he ta l .[ 65] studied insulin
responsiveness in adipocytes and skeletal muscle of mature
rats rendered hypothyroid by a low iodine diet and propylth-
iouracil. It was observed that glucose conversion to glycogen
was partially inhibited while the glycolytic ﬂux stimulation
by insulin was totally frustrated. This decrease in insulin
sensitivity occurred without an impaired membrane insulin
eﬀector system. Other authors [66, 67] showed decreased
insulin-stimulated glucose transport and/or phosphoryla-
tion, as well as a lower rate of glycolysis in the isolated,
incubated soleus muscle of the hypothyroid rat and also
suggested that the eﬀects of hypothyroidism in muscle were
notmediatedthroughaninterferenceofinsulinbindingtoits
receptor. It was postulated that they rather occurred through
a postreceptor mechanism that may include abnormal
phosphorylation of insulin signaling proteins.
Insulin resistance was conﬁrmed in another study of
rats with mild hypothyroidism [69]. In this study, insulin
responsiveness was measured by an insulin tolerance test and6 Journal of Thyroid Research
an euglycemic-hyperinsulinemic clamp followed by mea-
surements of tissue-speciﬁc glucose utilization indices with
the labelled 2-deoxy-D-[1-3H]glucose (2-DG) technique in
muscles (red quadriceps) and white adipose tissue (epididy-
mal fat). Several other parameters were also determined such
as muscle triglyceride content, plasma leptin and nonester-
iﬁed fatty acids (NEFA) levels, and mRNA expression of
resistin in adipose tissue as well as adipose tissue and liver
carnitine palmitoyl transferase 1α (CPT-1α), and muscle
carnitine palmitoyl transferase 1β (CPT-1β) mRNA levels,
explored by real-time quantitative PCR. Plasma leptin levels
were lower and adipose tissue mRNA expression of resistin
higher, in the hypothyroid state. Looking for a potential role
of leptin in the metabolic consequences of hypothyroidism,
leptin was infused, and it was found that glucose disposal
was recovered. Increased expression of muscle and adipose
tissue carnitine palmitoyl transferases, decreased plasma
NEFA levels, and reduced muscle triglyceride content after
leptin infusion were interpreted as the mediators of the
recovery of the insulin resistant state. Therefore, one possible
explanation to decreased insulin responsiveness in hypothy-
roidism, according to the authors of this study, includes a
dysregulation of leptin action at the hypothalamus.
Adipocyte-myocyte crosstalk by adipokines has been
reported to play a signiﬁcant role in skeletal muscle insulin
resistanceandmaypartiallyexplaininsulinresistancepresent
in hypothyroidism [70]. However, other factors associated
with insulin resistance in hypothyroidism, such as altered
blood ﬂow, impaired GLUT4 translocation, decreased glyco-
gen synthesis, and decreased muscle oxidative capacity have
to be also considered [71].
4.2. Studies in Humans Demonstrating Insulin Resistance
in Hypothyroidism. Compared to the number of reports
about insulin resistance in hyperthyroid patients, there are
relatively fewer studies in humans dealing with the eﬀects
of hypothyroidism on glucose metabolism. Rochon et al.
[72] measured whole-body sensitivity of glucose disposal
to insulin in hypothyroid patients using the euglycemic-
hyperinsulinemic clamp technique. They demonstrated that
hypothyroidism induced a decrease in the insulin-mediated
glucosedisposalthatrevertedupontreatment.Similarresults
were obtained by Stanick´ a et al. [73]. By means of the
same clamp technique and also measuring glucose tolerance
and beta-cell activity with an oral glucose tolerance tests
(OGTT),Handisuryaetal.[74]conﬁrmedtheseﬁndingsand
added the knowledge that glucose-induced insulin secretion
is diminished by thyroid replacement corresponding well
with the observed improvement of insulin sensitivity.
Dimitriadis et al. [75] explored glucose uptake in muscle
and adipose tissue of hypothyroid and control subjects
by means of the arteriovenous diﬀerence technique in the
anterior abdominal subcutaneous adipose tissue and the
forearm muscles after the consumption of a mixed meal.
A decreased net extraction of glucose and blood ﬂow after
the meal in hypothyroid muscle and adipose tissue was
reported.Thisimpairmentintheabilityofinsulintoincrease
blood ﬂow rate to the hypothyroid tissues is an alternative
explanation to the mechanism whereby hypothyroidism
can induce lower glucose disposal. The short i.v. insulin
tolerance test has been used to explore insulin sensitivity
in acute overt hypothyroid patients. Compared to euthyroid
controls, hypothyroid patients had a signiﬁcantly lower
glucose disposal [76].
Some negative results, however, in this ﬁeld have been
reported. A previous study in overt hypothyroid patients
based on the homeostasis model assessment (HOMA-IR)
[77] showed no association between hypothyroidism and
insulin sensitivity. Moreover, Harris et al. [78] found unim-
paired insulin-stimulated glucose disposal in the forearm of
hypothyroid patients after treatment with levothyroxine.
4.3. Subclinical Hypothyroidism. With regards to subclinical
hypothyroidism, insulin resistance has been demonstrated
in some [60, 74, 79] but not all studies, where HOMA
levels were found comparable to a control group [80–
82]. However, in some of these negative studies [80, 81],
hyperinsulinemia was reported in subclinical hypothyroid
subjects and interpreted as an early sign of impairment of
glucose metabolism.
5. Conclusions
Thyroid hormones have a large impact on glucose
metabolism. A direct regulation on thyroid responsive genes
at the target organ has been described and more recently an
indirecteﬀectinvolvinghypothalamicpathwaysthatregulate
glucose metabolism via control of the sympathetic nervous
system has been reported. Furthermore, thyroid hormone
eﬀects can be insulin agonistic, such as demonstrated in
muscle or antagonistic such as observed in the liver. In
hyperthyroidism, dysregulation of this balance may end in
glucose intolerance mainly due to hepatic insulin resistance.
In hypothyroidism the results are less evident. However, the
availabledatasuggestthatinsulinresistanceispresentmainly
at the peripheral tissues. Possible explanations hypothesized
to explain this phenomenon span from the dysregulation
of mitochondrial oxidative metabolism to the reduction of
blood ﬂow in muscle and adipose tissue under hypothyroid
conditions.
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